Q32 Bio (QTTB) Stock
Biotech company developing gene therapies for rare genetic diseases. Here's the price, business snapshot, and what's worth knowing about Q32 Bio in August 2026.
Homology Medicines Inc (QTTB) is a small-cap biotechnology company focused on developing gene editing and gene therapy approaches for rare genetic diseases. With a market capitalisation around $36.2 million, it is an early-stage developer: clinical data, regulatory milestones, partnerships and financing will be the main drivers of value. Investors should expect high volatility, potential dilution from future fundraising and long timelines typical of biotech development. Key areas to watch include cash runway, trial results, intellectual property position and competitor activity in similar gene therapies. The company’s prospects hinge on scientific validation and regulatory approvals — outcomes that are inherently uncertain. This summary is general, educational information only and not personalised investment advice; values can rise or fall and past performance is not a reliable indicator of future returns. Consider your risk tolerance and seek independent financial advice before making investment decisions.
About This Stock
Q32 BIO INC
QTTB
Current Price
$15.63
Potential 12 Month Profit
145.63%
Sector
N/A
Industry
N/A
Ticker
QTTB
Market Cap
$471.55M
Potential 12 Month Profit
145.63%
Sector
N/A
Industry
N/A
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Homology Medicines' stock with a target price of $16.25, indicating strong growth potential.
Financial Health
Homology Medicines is showing reasonable financial performance, but there are areas that need improvement.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Early-stage gene platform
Focuses on gene editing and therapy programmes; scientific validation can materially affect valuation, though outcomes are uncertain.
Data drives value
Clinical readouts, regulatory steps and partnerships tend to move the share price; investors should expect volatility and binary outcomes.
Balance risk and reward
Small market capitalisation and limited resources create upside and downside potential; consider runway and dilution risk before investing.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.